Porta, Camillo
Cosmai, Laura
Leibovich, Bradley C.
Powles, Thomas
Gallieni, Maurizio http://orcid.org/0000-0002-2011-2160
Bex, Axel
Article History
First Online: 26 March 2019
Competing interests
: C.P. and A.B. contributed to the European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) discussion regarding approval of sunitinib as an adjuvant treatment for resected renal cell carcinoma. The other authors declare no competing interests.